Skip to main content

Advertisement

Table 3 Frequency of the most common adverse events during the single dose study

From: Phase I randomized dose-ascending placebo-controlled trials of ferroquine - a candidate anti-malarial drug - in adults with asymptomatic Plasmodium falciparum infection

System organ class Preferred term Single Dose Study
   Placebo Ferroquine
   (N = 10) 400 mg (N = 6) 800 mg (N = 6) 1200 mg (N = 6) 1400 mg (N = 6) 1600 mg (N = 6)
Any class Any TEAE 9 (90) 3 (50) 1 (17) 6 (100) 6 (100) 4 (67)
Gastrointestinal disorders Any TEAE 4 (40) 0 0 3 (50) 4 (67) 4 (67)
  Abdominal pain 3 (30) 0 0 0 3 (50) 2 (33)
  Diarrhoea 0 0 0 1 (17) 2 (33) 0
  Nausea 1 (10) 0 0 1 (17) 1 (17) 2 (33)
  Toothache 1 (10) 0 0 1 (17) 0 0
  Vomiting 0 0 0 1 (17) 1 (17) 2 (33)
Nervous system disorders Any TEAE 2 (20) 0 0 3 (50) 1 (17) 3 (50)
  Dizziness 1 (10) 0 0 0 1 (17) 2 (33)
  Headache 1 (10) 0 0 3 (50) 1 (17) 1 (17)
  1. NOTE: N (%): count of patients (percentage per group); TEAE: treatment emergent adverse event